Dexcom shares fall on slow revenue growth

Dexcom shares fall on slow revenue growth
DexCom shares tumble nearly 40% after company cuts sales forecast
We started the year with data showing a recession was likely 2024 or later, and that meant rates were "higher for longer". So far, the data tells the same story, but there is one early read-through that is a red flag. https://t.co/oMi4gKp1GN $MU $RH $PLAY $LULU $DXCM $SPY… https://t.co/ngFxZGxSjG
DexCom gains after rejecting market rumors on M&A deal; Insulet drops
28.99BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US2521311074
CUSIP
252131107
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
32.27
PEG Ratio
1.40
Book Value
7.66
Dividend Share
-
Dividend Yield
-
Earnings Share
2.31
Wall Street Target Price
86.16
EPS Estimate Current Year
2.59
EPS Estimate Next Year
3.08
EPS Estimate Current Quarter
0.4706
EPS Estimate Next Quarter
0.6031
Most Recent Quarter
-
Revenue TTM
4,817,900,032
Gross Profit TTM
2,963,200,000
EBITDA
1,292,300,032
Profit Margin
19.31%
Return On Assets TTM
9.65%
Return On Equity TTM
35.62%
Revenue Per Share TTM
12.395
Qtly Revenue Growth YOY
15.00%
Diluted Eps TTM
2.31
Qtly Earnings Growth YOY
92.20%
Trailing PE
32.27
Forward PE
29
Price Sales TTM
5.97
Price Book MRQ
9.8057
Enterprise Value Revenue
5
Enterprise Value EBITDA
18
46.68
2.00%21.51
0.37%105.90
0.12%85.69
0.05%25.07
0.00%43.47
0.00%325.70
-6.42%67.99
-2.93%26.10
-1.34%86.07
-1.01%